Amgen's Evenity (romosozumab-aqqg) Receives FDA's Approval for Osteoporosis in Postmenopausal Women at High Risk for Fracture
Shots:
- The FDA’s approval is based on two P-III FRAME & ARCH studies result assessing Evenity (210mg) vs PBO & alendronate (70mg) in 7-180 & 4-093 postmenopausal women with osteoporosis respectively
- The P-III FRAME & ARCH study results: @12mos. and 24mos. significant reduction in vertebral (spine) fracture; @33 mos. reduction in risk of clinical fracture; increment in bone mineral density (BMD) at the lumbar spine- total hip- and femoral neck @12mos.
- Evenity (romosozumab-aqqg) is a mAb- inhibits sclerostin resulting in an increment of bone formation and decreases in bone resorption and is collaboratory developed by Amgen and UCB. Evenity also has a boxed warning in its label as it increases the risk for MI- stroke- & cardiovascular death
Ref: Amgen | Image: Twitter
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com